<DOC>
	<DOCNO>NCT00001676</DOCNO>
	<brief_summary>This study test safety effectiveness combination therapy cyclophosphamide ( Cytoxan ) fludarabine treat lupus nephritis ( kidney inflammation ) . This condition , common patient systemic lupus erythematosus , cause abnormal action immune cell call lymphocyte kidney . Left untreated , severe case result loss kidney function . The current treatment choice-intermittent high dos ( pulse ) cyclophosphamide-does work patient cause infertility many woman . The rate infertility men know . This study examine whether fludarabine safely give significantly low dos cyclophosphamide , combination control kidney inflammation . Patients 18 year age old severe lupus nephritis ( call proliferative lupus nephritis ) may eligible study . Candidates history physical examination ; blood urine test ; chest X-ray ; electrocardiogram ; cancer screening may include Pap smear , mammogram , rectal examination , PSA testing , sigmoidoscopy . Participants divide one follow treatment group : Group 1-Patients undergo three treatment cycle cyclophosphamide , take mouth , fludarabine , inject subcutaneously ( skin ) . Patients receive drug day 1 cycle , fludarabine alone day 2 3 . This regimen repeat every 5 week three cycle . Group 2-Same Group 1 , except fludarabine injection give intravenously ( vein ) second treatment cycle . Patients group frequent blood sample first second treatment cycle monitor blood level drug . Samples collect first injection give 0.5 , 1 , 1.5 , 2 , 4 , 8 , 24 48 hour third injection . A total 12 tablespoon blood draw 2-month period . All patient blood draw twice week first two cycle less frequently monitor blood count . Some patient follow additional procedure test effect treatment lymphocytes : 1 . Blood sample collection 2 . Bone marrow aspiration-The skin hip bone clean local anesthetic inject outer cover bone . Bone marrow suction needle attached syringe . The procedure do treatment begin , end treatment , 6 month treatment . 3 . Tonsillar biopsy-The tonsil numb local anesthetic 1 4 piece tissue remove use special forceps . The procedure do treatment begin , end treatment , 6 month treatment . 4 . Magnetic resonance imaging ( MRI ) abdomen-The patient lie table narrow cylinder ( MRI scanner ) contain strong magnetic field , use create image part body small section view . Patients follow least 24 month monitor late side effect response treatment .</brief_summary>
	<brief_title>Cyclophosphamide Fludarabine Treat Lupus Nephritis</brief_title>
	<detailed_description>Studies NIH Clinical Center show intermittent pulse cyclophosphamide therapy effective treating patient severe lupus nephritis , may result substantial rate sustain amenorrhea . Initial study patient autoimmune rheumatic disease also suggest beneficial effect lymphocyte-specific nucleoside analog chlorodeoxyadenosine fludarabine . Cyclophosphamide induce DNA cross-link whereas , nucleoside analogs inhibits DNA repair indicate complementary partially synergistic mode action . Whether combination low dos cyclophosphamide nucleoside analogs increase efficacy time minimize toxicity higher-cumulative dos cyclophosphamide determine . In phase I/II study , 15 patient proliferative lupus nephritis treat outpatient combination oral cyclophosphamide ( 500 mg/m ( 2 ) ) day 1 follow fludarabine ( 30 mg/m ( 2 ) ) subcutaneously day 1 , 2 3 every month 3 cycle . The cumulative dose cyclophosphamide regimen approximately 2.5g compare great equal 30g standard NIH cyclophosphamide regimen . In study tolerance toxicity combination study . Regeneration T B cell follow depletion include analysis antigen-repertoire function also examine . Preliminary efficacy information , include rate time renal remission rate preservation renal function , analyze use future control study . Pharmacokinetic analysis perform subset patient determine bioavailability pharmacokinetic parameter subcutaneous fludarabine .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must 18 year age older able provide inform consent . Patients must least 4 criterion SLE define American Rheumatism Association ( ARA ) . Active glomerulonephritis : Renal biopsy within 1 year class III class IV active lupus nephritis , AND ; Abnormal urine analysis : Greater 10 RBC/hpf cellular ( RBC , WBC mix ) cast , OR ; Greater 10 RBC/hpf proteinuria great 2 g/day , OR ; Proteinuria great 3.5 g/day . No patient severe proliferative lupus nephritis : a. active renal histology crescent necrosis 25 % glomerulus ; b. rapidly progressive glomerulonephritis ( double serum creatinine less equal 3 month ) ; c. severe impairment renal function Cr great 2.5 mg/dL GFR le 50 mL/min measure inulin clearance . Patient previous immunosuppressive therapy : Patients must receive azathioprine , cyclosporine , methotrexate . Patients receive drug eligible drug discontinue wait period great equal 4 week ; Patients must receive cyclophosphamide : Greater 3 pulse ( maximum 1 g/m ( 2 ) /pulse ) within last 12 month since last renal biopsy show active disease ; OR great 6 pulse ever . Patients must pulse therapy glucocorticoid experimental therapy 4 week study entry . Patients need study entry oral corticosteroid dosage great 0.5 mg/kg/day predisone control extrarenal disease eligible . Patients active chronic infection eligible . Patients pregnant , breastfeed use inadequate birth control eligible . Patients poorly control diabetes mellitus evidence endorgan damage eligible . No history cerebrovascular accident , seizures within last 5 year chronic neurologic disease . No history malignancy squamous cell and/or basal carcinoma skin . No confound medical illness judgment investigator would pose added risk study participant : Unstable coronary artery disease , cardiomyopathy dysrhythmia require therapy ; Pulmonary disease ( PFTs less 70 % predict value DLCO le 60 % ) , ; Hematologic disease ( Hb le 8 mg/dL , platelets less 100,000 micro liter WBC le 2,500/micro liter .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>Remission</keyword>
	<keyword>Renal Function</keyword>
	<keyword>Infection</keyword>
	<keyword>Germinal Center</keyword>
	<keyword>Immunoglobulin</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Lupus Nephritis</keyword>
</DOC>